Seminars in Nephrology
Volume 26, Issue 6 , Pages 434-440 , November 2006

Mineralocorticoid Hypertension and Hypokalemia

  • Neenoo Khosla

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Neenoo Khosla, MD, Assistant Professor, Division of Nephrology/Hypertension, Northwestern University Feinberg School of Medicine, 710 North Fairbanks, Suite 4-500, Chicago, IL 60611.
    • ,
  • Donn Hogan

References 

  1. Hall JE, Granger JP, Smith MJ, et al. Role of renal hemodynamics and arterial pressure in aldosterone “escape”. Hypertension. 1984;6:I183–I1192
  2. White PC, New MI, Dupont B. Congenital adrenal hyperplasia. N Engl J Med. 1987;316:1519–1522
  3. White PC. Disorders of aldosterone biosynthesis and action. N Engl J Med. 1994;331:250
  4. Mitra A, Batlle D. Aldosterone deficiency and resistance (acid-base and electrolyte disorders). In:  Du Bose, Hamm  editor. A Companion to Brenner and Rector’s the Kidney. Philadelphia: Saunders; 2002;p. 413–433
  5. Batlle D, Kurtzman N. Clinical disorders of aldosterone metabolism. Dis Mon. 1984;30(8):1–55
  6. Taymans SE, Pack S, Pak E, et al. Human CYP11B2 (aldosterone synthase) maps to chromosome 8q24.3. J Clin Endocrinol Metab. 1998;83:1033
  7. Minuth WW, Gilbert P, Gross P. Appearance of specific proteins in the apical plasma membrane of cultured renal collecting duct principal cell epithelium after chronic administration of aldosterone and arginine vasopressin. Differentiation. 1988;38:194
  8. Verrey F. Early aldosterone action: Toward filling the gap between transcription and transport. Am J Physiol. 1999;277:F319
  9. Masilamani S, Kim GH, Mitchell C, et al. Aldosterone-mediated regulation of ENaC alpha, beta, and gamma subunit proteins in rat kidney. J Clin Invest. 1999;104:R19
  10. Shimkets RA, Lifton R, Canessa CM. In vivo phosphorylation of the epithelial sodium channel. Proc Natl Acad Sci U S A. 1998;95:3301
  11. Hays SR. Mineralocorticoid modulation of apical and basolateral membrane H+/OH−/HCO3− transport processes in rabbit inner stripe of outer medullary collecting duct. J Clin Invest. 1992;90:180
  12. Funder JW. Mineralocorticoids, glucocorticoids, receptors and response elements. Science. 1993;259:1132
  13. Kenouch S, Coutry N, Farman N, et al. Multiple patterns of 11β-hydroxysteroid dehydrogenase catalytic activity along the mammalian nephron. Kidney Int. 1992;42:56
  14. Stewart P. Mineralocorticoid hypertension. Lancet. 1999;353:1341–1347
  15. Mulatero P, Dluhy RG, Giacchetti G, et al. Diagnosis of primary aldosteronism: From screening to subtype differentiation. Trends Endocrinol Metab. 2005;16:114–119
  16. Mosso L, Carvajal C, Gonzalez A, et al. Primary hyperaldosteronism and hypertensive disease. Hypertension. 2003;42:161–165
  17. Hiramatsu K, Yamada T, Yukimura Y, et al. A screening test to identify aldosterone producing adenoma by measuring plasma renin activity: Results in hypertensive patients. Arch Intern Med. 1981;141:1589–1593
  18. Brown M, Cramp H, Zammit V, et al. Primary hyperaldosteronism: A missed diagnosis in essential hypertensives?. Aust N Z J Med. 1996;26:533–538
  19. Fardella C, Mosso L, Gomez-Sanchez C, et al. Primary hyperaldosteronism in essential hypertensives: Prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab. 2000;85:1863–1867
  20. Gallay B, Ahmad S, Xu L, et al. Screening for primary hyperaldosteronism without discontinuing hypertensive medications: Plasma aldosterone-renin ratio. Am J Kidney Dis. 2001;37:699–705
  21. Gordon R, Ziesak M, Tunny T, et al. Evidence that primary aldosteronism may not be uncommon: 12% incidence among antihypertensive drug trial volunteers. Clin Exp Pharmacol Physiol. 1993;20:296–298
  22. Hamlet S, Tunny T, Woodland E, et al. Is aldosterone/renin ratio useful to screen a hypertensive population?. Clin Exp Pharmacol Physiol. 1985;12:249–252
  23. Kreze A, Okalova D, Vanuga P, et al. Occurrence of primary aldosteronism in a group of ambulatory hypertensive patients. Vnitr Lek. 1999;45:17–21
  24. Kumar A, Lall S, Ammini A, et al. Screening of a population of young hypertensives for primary hyperaldosteronism. J Hum Hypertens. 1994;8:731–732
  25. Lazurova I, Schwartz P, Trejbal D, et al. Incidence of primary aldosteronism in hospitalized hypertensive patients. Bratisl Lek Listy. 1999;100:200–203
  26. Lim P, Dow E, Jung R, et al. Prevalence of primary aldosteronism in the tayside hypertension clinic population. J Hum Hypertens. 2000;14:311–315
  27. Loh K, Koay E, Khaw M, et al. Prevalence study on primary aldosteronism among Asian hypertensive patients in Singapore. J Clin Endocrinol Metab. 2000;85:2854–2859
  28. Mosso L, Fardella C, Montero J, et al. High prevalence of undiagnosed primary aldosteronism among patients with essential hypertension. Rev Med Chil. 1999;127:800–806
  29. Rossi G, Rossi E, Pavan E, et al. Screening for primary aldosteronism with a logistic multivariate discriminate analysis. Clin Endocrinol. 1998;49:713–723
  30. Gordon R, Stowasser M, Tunny T. High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin Exp Pharmacol Physiol. 1994;21:315–318
  31. Lim P, Rodgers P, Cardale K, et al. Potentially high prevalence of primary aldosteronism in a primary-care population. Lancet. 1999;353:40
  32. Montori V, Young W. Use of plasma aldosterone concentration-to-plasma renin activity ratio as a screening test for primary aldosteronism (A systematic review of the literature). Endocrinol Metab Clin North Am. 2002;31:619–632
  33. Weinberger M, Fineberg N. The diagnosis of primary aldosteronism and separation of two major subtypes. Arch Intern Med. 1993;153:2125–2129
  34. Young W. Primary aldosteronism (A common and curable form of hypertension). Cardiol Rev. 1999;7:207–214
  35. Tiu T, Choi C, Shek C, et al. The use of aldosterone-renin ratio as a diagnostic test for primary hyperaldosteronism and its test characteristics under different conditions of blood sampling. J Clin Endocrinol Metab. 2005;90:72–78
  36. Lyons D, Kem D, Brown R, et al. Single dose captopril as a diagnostic test for primary aldosteronism. J Clin Endocrinol Metab. 1983;57:892–896
  37. Nadler J, Hsueh W, Horton R. Therapeutic effect of calcium channel blockade in primary aldosteronism. J Clin Endocrinol Metab. 1985;60:896–899
  38. Gleason PE, Weinberger MH, Pratt JH, et al. Evaluation of diagnostic tests in the differential diagnosis of primary aldosteronism: Unilateral adenoma versus bilateral micronodular hyperplasia. J Urol. 1993;150:1365
  39. Radin DR, Manoogian C, Nadler JL. Diagnosis of primary hyperaldosteronism: Importance of correlating CT findings with endocrinologic studies. AJR Am J Roentgenol. 1992;158:553
  40. Doppman JL, McGill JR, Miller DL, et al. Distinction between hyperaldosteronism due to bilateral hyperplasia and unilateral aldosteronoma: Reliability of CT. Radiology. 1992;184:677
  41. Young WF, Stanson AW, Thompson GB, et al. Role for adrenal venous sampling in primary aldosteronism. Surgery. 2004;136:1227
  42. Lumachi F, Ermani M, Basso SM, et al. Long-term results of adrenalectomy in patients with aldosterone-producing adenomas: Multivariate analysis of factors affecting unresolved hypertension and review of the literature. Am Surg. 2005;71:864–869
  43. Sawka AM, Young WF, Thompson GB, et al. Primary aldosteronism: Factors associated with normalization of blood pressure after surgery. Ann Intern Med. 2001;135:258–261
  44. Minowada S, Fujimura T, Takahashi N, et al. Computed tomography-guided percutaneous acetic acid injection therapy for functioning adrenocortical adenoma. J Clin Endocrinol Metab. 2003;88:5814
  45. Kawasaki T, Omae T, Tanaka K, et al. Remission or recurrent hyperaldosteronism resulting from subtotal adrenalectomy of adenomatous hyperplastic adrenal glands. J Clin Endocrinol Metab. 1971;33:474–480
  46. Ghose RP, Hall PM, Bravo EL. Medical management of aldosterone-producing adenomas. Ann Intern Med. 1999;131:105–108
  47. Rossi GP, Sacchetto A, Pavan E, et al. Remodeling of the left ventricle in primary aldosteronism due to Conn’s adenoma. Circulation. 1997;95:1471–1478
  48. Rich GM, Ulick S, Cook S, et al. Glucocorticoid-remediable aldosteronism in a large kindred: Clinical spectrum and diagnosis using a characteristic biochemical phenotype. Ann Intern Med. 1992;116:813
  49. Lifton RP, Dluhy RG, Powers M, et al. A chimeric 11β-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature. 1992;355:262
  50. Pascoe L, Curnow KM, Slutsker L, et al. Glucocorticoid-suppressible hyperaldosteronism results from hybrid genes created by unequal crossovers between CYP11B1 and CYP11B2. Proc Natl Acad Sci U S A. 1992;89:8327–8331
  51. McMahon GT, Dluhy RG. Glucocorticoid-remediable aldosteronism. Cardiol Rev. 2004;12:44–48
  52. Dluhy RG, Lifton RP. Glucocorticoid-remediable aldosteronism (GRA): Diagnosis, variability of phenotype and regulation of potassium homeostasis. Steroids. 1995;60:48–51
  53. Litchfield WR, Anderson BF, Weiss RJ, et al. Intracranial aneurysm and hemorrhagic stroke in glucocorticoid-remediable aldosteronism. Hypertension. 1998;31:445–450
  54. Stewart PM, Corrie JE, Shackleton CH, et al. Syndrome of apparent mineralocorticoid excess (A defect in the cortisol-cortisone shuttle). J Clin Invest. 1988;82:340–349
  55. Quinkler M, Stewart PM. Hypertension and the cortisol-cortisone shuttle. J Clin Endocrinol Metab. 2003;88:2384–2392
  56. Dave-Sharma S, Wilson RC, Harbison MD, et al. Examination of genotype and phenotype relationships in 14 patients with apparent mineralocorticoid excess. J Clin Endocrinol Metab. 1998;83:2244–2254
  57. Wilson RC, Krozowski ZS, Li K, et al. A mutation in the HSD11B2 gene in a family with apparent mineralocorticoid excess. J Clin Endocrinol Metab. 1995;80:2263–2266
  58. Mariniello B, Ronconi V, Sardu C, et al. Analysis of the 11beta-hydroxysteroid dehydrogenase type 2 gene (HSD11B2) in human essential hypertension. Am J Hypertens. 2005;18:1091–1098
  59. Palermo M, Cossu M, Shackelton CHL. Cure for apparent mineralocorticoid excess by kidney transplantation. N Engl J Med. 1998;329:1787–1788
  60. Farese RV, Biglieri EG, Gomez FR, et al. Licorice- induced hypermineralocorticoidism. N Engl J Med. 1991;325:1223–1227
  61. Whorwood CB, Sheppard MC, Stewart P. Licorice inhibits 11 beta-hydroxysteroid dehydrogenase messenger ribonucleic acid levels and potentiates glucocorticoid hormone action. Endocrinology. 1993;132:2287–2292
  62. Ulick S, Wang JZ, Blumenfeld JD, et al. Cortisol inactivation overload: A mechanism of mineralocorticoid hypertension in the ectopic adrenocorticotropin syndrome. J Clin Endocrinol Metab. 1992;74:963–967
  63. Williams TA, Mulatero P, Filigheddu F, et al. Role of HSD11B2 polymorphisms in essential hypertension and the diuretic response to thiazides. Kidney Int. 2005;67:63–67
  64. Mariniello B, Ronconi V, Sardu C, et al. Analysis of the 11beta-hydroxysteroid dehydrogenase type 2 gene (HSD11B2) in human essential hypertension. Am J Hypertens. 2005;18:1091–1098

PII: S0270-9295(06)00144-6

doi: 10.1016/j.semnephrol.2006.10.004

Seminars in Nephrology
Volume 26, Issue 6 , Pages 434-440 , November 2006

Article Tools